New Weight-Loss drug candidate enters early human testing
NCT ID NCT06606106
First seen Nov 01, 2025 · Last updated May 28, 2026 · Updated 24 times
Summary
This early-stage study tests a new drug called LY3537031 in overweight, obese, and healthy volunteers. The main goal is to check safety and side effects, but researchers will also measure how much drug gets into the blood and how body weight changes. The study lasts about 49 weeks and includes up to 302 participants.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for OBESITY are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Clinical Pharmacology of Miami
Miami, Florida, 33172, United States
-
Collaborative Neuroscience Research, LLC
Los Alamitos, California, 90720, United States
-
Fortrea Clinical Research Unit
Daytona Beach, Florida, 32117, United States
-
Fortrea Clinical Research Unit
Dallas, Texas, 75247, United States
-
QPS
Springfield, Missouri, 65802, United States
Conditions
Explore the condition pages connected to this study.